0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%
Last update at 2024-11-21T20:54:00Z
Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase
Fri 18 Oct 24, 07:26 PMBristol-Myers Squibb Company (BMY): A Bull Case Theory
Thu 17 Oct 24, 02:48 PMWave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
Thu 17 Oct 24, 11:33 AMBernstein starts healthcare sector, rates three stocks as Buy
Thu 17 Oct 24, 10:05 AMBristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
Fri 11 Oct 24, 09:45 PMTop Research Reports for Bristol-Myers, Arthur J. Gallagher & TC Energy
Fri 11 Oct 24, 08:29 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7713.00M | 8098.00M | -6871.00000M | 4975.00M | 6010.00M |
| Minority interest | -18.00000M | -20.00000M | 20.00M | 21.00M | 27.00M |
| Net income | 6327.00M | 6994.00M | -8995.00000M | 3439.00M | 4952.00M |
| Selling general administrative | 7808.00M | 7688.00M | 7661.00M | 4871.00M | 4551.00M |
| Selling and marketing expenses | 7814.00M | 7690.00M | 7661.00M | 4871.00M | 4551.00M |
| Gross profit | 36022.00M | 36445.00M | 30745.00M | 18067.00M | 16014.00M |
| Reconciled depreciation | 9595.00M | 10023.00M | 10380.00M | 1746.00M | 637.00M |
| Ebit | 10328.00M | 10159.00M | 5128.00M | 5464.00M | 5434.00M |
| Ebitda | 19923.00M | 20182.00M | 14816.00M | 6599.00M | 6071.00M |
| Depreciation and amortization | 9595.00M | 10023.00M | 9688.00M | 1135.00M | 637.00M |
| Non operating income net other | -576.00000M | 720.00M | 2314.00M | -938.00000M | 850.00M |
| Operating income | 10328.00M | 10159.00M | 5128.00M | 5464.00M | 5118.00M |
| Other operating expenses | 37055.00M | 37848.00M | 40341.00M | 20232.00M | 17443.00M |
| Interest expense | 1232.00M | 1334.00M | 1420.00M | 656.00M | 183.00M |
| Tax provision | 1368.00M | 1084.00M | 2124.00M | 1515.00M | 1021.00M |
| Interest income | 1862.00M | 550.00M | 71.00M | 69.00M | 380.00M |
| Net interest income | -1232.00000M | -1334.00000M | -1420.00000M | -656.00000M | -183.00000M |
| Extraordinary items | - | - | - | 0.00000M | -56.00000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1368.00M | 1084.00M | 2124.00M | 1515.00M | 1031.00M |
| Total revenue | 46159.00M | 46385.00M | 42518.00M | 26145.00M | 22561.00M |
| Total operating expenses | 26918.00M | 27908.00M | 28568.00M | 12154.00M | 10896.00M |
| Cost of revenue | 10137.00M | 9940.00M | 11773.00M | 8078.00M | 6547.00M |
| Total other income expense net | -2615.00000M | -2061.00000M | -11999.00000M | -489.00000M | 1075.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 6345.00M | 7014.00M | -8995.00000M | 6490.00M | 4947.00M |
| Net income applicable to common shares | 6327.00M | 6994.00M | -9015.00000M | 3439.00M | 4920.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 96820.00M | 109314.00M | 118481.00M | 129944.00M | 10659.00M |
| Intangible assets | 36355.00M | 42775.00M | 53243.00M | 63969.00M | 1091.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1596.00M | 1290.00M | 1368.00M | 1983.00M | 1116.00M |
| Total liab | 65702.00M | 73308.00M | 80599.00M | 78246.00M | 7349.00M |
| Total stockholder equity | 31061.00M | 35946.00M | 37822.00M | 51598.00M | 14031.00M |
| Deferred long term liab | 2166.00M | 4501.00M | 5407.00M | 6454.00M | 468.00M |
| Other current liab | 13106.00M | 10109.00M | 10241.00M | 7888.00M | -2064.00000M |
| Common stock | 292.00M | 292.00M | 292.00M | 292.00M | 221.00M |
| Capital stock | 292.00M | 292.00M | 292.00M | 292.00M | 221.00M |
| Retained earnings | 25503.00M | 23820.00M | 21281.00M | 34474.00M | 34065.00M |
| Other liab | 7392.00M | 10961.00M | 12340.00M | 15882.00M | 4544.00M |
| Good will | 21149.00M | 20502.00M | 20547.00M | 22488.00M | 6538.00M |
| Other assets | 2877.00M | 3342.00M | 7328.00M | 4834.00M | 2165.00M |
| Cash | 9123.00M | 13979.00M | 14546.00M | 12346.00M | 6911.00M |
| Cash and equivalents | 9123.00M | 13979.00M | 14546.00M | 12346.00M | 6911.00M |
| Total current liabilities | 21890.00M | 21868.00M | 19080.00M | 18304.00M | 1703.00M |
| Current deferred revenue | 1344.00M | 3693.00M | 3622.00M | 4492.00M | 172.00M |
| Net debt | 31594.00M | 31617.00M | 37127.00M | 35192.00M | 438.00M |
| Short term debt | 4400.00M | 5117.00M | 2504.00M | 3479.00M | 1703.00M |
| Short long term debt | 4264.00M | 4948.00M | 2340.00M | 3346.00M | 1703.00M |
| Short long term debt total | 40717.00M | 45596.00M | 51673.00M | 47538.00M | 7349.00M |
| Other stockholder equity | 6547.00M | 13102.00M | 18088.00M | 18352.00M | -17493.00000M |
| Property plant equipment | 6255.00M | 6049.00M | 5886.00M | 6252.00M | 5027.00M |
| Total current assets | 27273.00M | 33262.00M | 30192.00M | 29354.00M | 8884.00M |
| Long term investments | 2187.00M | 2713.00M | 433.00M | 767.00M | 1775.00M |
| Net tangible assets | -25947.00000M | -28236.00000M | -35968.00000M | -34859.00000M | 6402.00M |
| Short term investments | 130.00M | 3242.00M | 1285.00M | 3047.00M | 1973.00M |
| Net receivables | 13937.00M | 12516.00M | 8501.00M | 7685.00M | 5965.00M |
| Long term debt | 35056.00M | 39605.00M | 48336.00M | 43387.00M | 5646.00M |
| Inventory | 2339.00M | 2095.00M | 2074.00M | 4293.00M | 1195.00M |
| Accounts payable | 3040.00M | 2949.00M | 2713.00M | 2445.00M | 1892.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 57.00M | 60.00M | 60.00M | 100.00M | 96.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1281.00000M | -1268.00000M | -1839.00000M | -1520.00000M | -2762.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 292.00M | 292.00M | 292.00M | 292.00M | 221.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 25503.00M | 23820.00M | 21281.00M | 34474.00M | 34065.00M |
| Treasury stock | - | -31259.00000M | -26237.00000M | -25357.00000M | -19574.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1037.00M | 1655.00M | 2084.00M | 6604.00M | -14027.00000M |
| Deferred long term asset charges | - | - | - | 510.00M | 1371.00M |
| Non current assets total | 69547.00M | 76052.00M | 88289.00M | 100590.00M | 1775.00M |
| Capital lease obligations | 1397.00M | 1043.00M | 997.00M | 805.00M | - |
| Long term debt total | 35056.00M | 39605.00M | 48336.00M | 43387.00M | 5646.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 3037.00M | 1297.00M | 2108.00M | -152.00000M | 74.00M |
| Change to liabilities | -887.00000M | 45.00M | -2117.00000M | 1136.00M | 103.00M |
| Total cashflows from investing activities | -1062.00000M | -538.00000M | -10859.00000M | -9770.00000M | -874.00000M |
| Net borrowings | -5311.00000M | -6182.00000M | 3928.00M | 17653.00M | -548.00000M |
| Total cash from financing activities | -16962.00000M | -16224.00000M | -1151.00000M | 7621.00M | -3535.00000M |
| Change to operating activities | -183.00000M | 606.00M | 1074.00M | 702.00M | 634.00M |
| Net income | 6345.00M | 7014.00M | -8995.00000M | 3460.00M | 4947.00M |
| Change in cash | -4991.00000M | -657.00000M | 2153.00M | 5909.00M | 1490.00M |
| Begin period cash flow | 14316.00M | 14973.00M | 12820.00M | 6911.00M | 5421.00M |
| End period cash flow | 9325.00M | 14316.00M | 14973.00M | 12820.00M | 6911.00M |
| Total cash from operating activities | 13066.00M | 16207.00M | 14052.00M | 8067.00M | 5940.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 10276.00M | 10686.00M | 10380.00M | 1746.00M | 637.00M |
| Other cashflows from investing activities | -2981.00000M | -862.00000M | -12214.00000M | -8782.00000M | 3.00M |
| Dividends paid | 4634.00M | 4396.00M | 4075.00M | 2679.00M | 2613.00M |
| Change to inventory | -69.00000M | 13.00M | 2672.00M | 463.00M | -216.00000M |
| Change to account receivables | -663.00000M | -2117.00000M | -2951.00000M | 1659.00M | -267.00000M |
| Sale purchase of stock | -8001.00000M | -6287.00000M | -1546.00000M | -7300.00000M | -320.00000M |
| Other cashflows from financing activities | 7104.00M | 641.00M | 542.00M | -53.00000M | -54.00000M |
| Change to netincome | -1078.00000M | -748.00000M | -197.00000M | -62.00000M | 901.00M |
| Capital expenditures | 1118.00M | 973.00M | 753.00M | 836.00M | 951.00M |
| Change receivables | -663.00000M | -1054.00000M | -646.00000M | 752.00M | -429.00000M |
| Cash flows other operating | -858.00000M | 251.00M | 12955.00M | 572.00M | -3.00000M |
| Exchange rate changes | - | - | - | - | -41.00000M |
| Cash and cash equivalents changes | -4958.00000M | -555.00000M | 2042.00M | 5918.00M | 1490.00M |
| Change in working capital | -2229.00000M | -1253.00000M | 983.00M | 3065.00M | 176.00M |
| Stock based compensation | 457.00M | 583.00M | 779.00M | 441.00M | 221.00M |
| Other non cash items | 955.00M | 570.00M | 9922.00M | 279.00M | -127.00000M |
| Free cash flow | 11948.00M | 15234.00M | 13299.00M | 7231.00M | 4989.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company |
0.34 0.58% | 58.22 | 13.27 | 6.99 | 2.31 | 3.66 | 3.06 | 7.03 |
| LLY Eli Lilly and Company |
-4.43 0.59% | 748.98 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
2.39 1.56% | 155.50 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
3.97 2.37% | 171.73 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| MRK Merck & Company Inc |
2.90 2.98% | 100.34 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
430 East 29th Street, New York, NY, United States, 10016
| Name | Title | Year Born |
|---|---|---|
| Dr. Giovanni Caforio M.D. | Chairman & CEO | 1965 |
| Mr. David V. Elkins | Exec. VP & CFO | 1968 |
| Ms. Sandra Leung Esq. | Exec. VP & Gen. Counsel | 1961 |
| Dr. Christopher S. Boerner | Exec. VP & Chief Commercialization Officer | 1971 |
| Mr. Rupert Vessey BCH, BM, DPHIL, M.A. | Exec. VP and Pres of Research & Early Devel. | 1965 |
| Mr. Greg Meyers | Exec. VP and Chief Digital & Technology Officer | 1973 |
| Mr. Timothy Power | VP & Head of Investor Relations | NA |
| Ms. Cari Gallman | Sr. VP & Chief Compliance and Ethics Officer | NA |
| Ms. Ann M. Powell Judge | Exec. VP & Chief HR Officer | 1966 |
| Mr. Jitendra Tyagi | Head of US Drug Makers - India | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...